Cargando…

Renal Salt Wasting in Patients Treated with High-Dose Cisplatin, Etoposide, and Mitomycin in Patients with Advanced Non-Small Cell Lung Cancer

Cisplatin has many toxic effects; emesis, impairment of renal function, myelosuppression, peripheral neuropathy, ototoxicity and renal tubular wasting. We used MVP regimen (Mitomycin C, Vp-16, and Cisplatin) in advanced Non-Small Cell Lung Cancer (NSCLC). Using hydration and prophylactic supplementa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Yong Koo, Shin, Dong Moon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Association of Internal Medicine 1992
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4532106/ https://www.ncbi.nlm.nih.gov/pubmed/1339077 http://dx.doi.org/10.3904/kjim.1992.7.2.118

Ejemplares similares

VIP (etoposide, ifosfamide, and cisplatin) in patients with previously treated soft tissue sarcoma
por: Moon, Ji Young, et al.
Publicado: (2017)

A case of small-cell esophageal cancer with chronic renal failure undergoing hemodialysis safely treated with cisplatin and etoposide
por: Murakami, Kentaro, et al.
Publicado: (2011)

Concomitant etoposide and cisplatin provided improved survival compared with docetaxel and cisplatin in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy
por: Sen, Fatma, et al.
Publicado: (2016)

Symptom relief with moderate dose chemotherapy (mitomycin-C, vinblastine and cisplatin) in advanced non-small cell lung cancer.
por: Hardy, J. R., et al.
Publicado: (1989)

A Phase III Randomized Study Comparing a Chemotherapy with Cisplatin and Etoposide to a Etoposide Regimen without Cisplatin for Patients with Extensive Small-Cell Lung Cancer
por: Berghmans, Thierry, et al.
Publicado: (2017)

Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancer
por: Yarchoan, Mark, et al.
Publicado: (2017)

Cisplatin Decreases ENaC Activity Contributing to Renal Salt Wasting Syndrome
por: Soares, Antonio G., et al.
Publicado: (2020)

An Exceptionally Favorable Response to Etoposide and Cisplatin
por: Valecha, Gautam, et al.
Publicado: (2015)

The efficacy and safety of irinotecan cisplatin and mitomycin chemotherapy in sunitinib pre-treated metastatic clear cell renal cancer
por: Powles, Thomas, et al.
Publicado: (2008)

Gemcitabine, Etoposide, Cisplatin, and Dexamethasone in Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma
por: Kim, Ki-Hyang, et al.
Publicado: (2009)

Profound hyponatremia and dehydration: A case of cisplatin induced renal salt wasting syndrome
por: George, Tissa Bijoy, et al.
Publicado: (2023)

Phase III randomized trial comparing moderate-dose cisplatin to combined cisplatin and carboplatin in addition to mitomycin and ifosfamide in patients with stage IV non-small-cell lung cancer
por: Sculier, J-P, et al.
Publicado: (2000)

Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702
por: Okamoto, H, et al.
Publicado: (2007)

Paclitaxel-etoposide-carboplatin/cisplatin versus etoposide-carboplatin/cisplatin as first-line treatment for combined small-cell lung cancer: a retrospective analysis of 62 cases
por: Li, Yue-Ya, et al.
Publicado: (2015)

Safety and efficacy of administering reduced doses of pegylated recombinant human granulocyte‐colony stimulating factors in patients treated with cisplatin and etoposide for small cell carcinoma: A retrospective study
por: Liu, Chang, et al.
Publicado: (2021)

Feasibility of combination chemotherapy with cisplatin and etoposide for haemodialysis patients with lung cancer
por: Watanabe, R, et al.
Publicado: (2003)

Association between cumulative cisplatin dose and reproductive and sexual functions in patients with malignant ovarian germ cell tumors treated with bleomycin, etoposide, and cisplatin therapy: a case series study
por: Akasaka, Miki, et al.
Publicado: (2022)

Recurrent Metastatic Choriocarcinoma Responsive to Etoposide and Cisplatin with Etoposide, Methotrexate, and Dactinomycin: A Case Report
por: Das, Sunil Kumar, et al.
Publicado: (2022)

Cisplatin-Induced Renal Salt Wasting Requiring over 12 Liters of 3% Saline Replacement
por: Pham, Phuong-Chi, et al.
Publicado: (2017)

Renal Salt-Wasting Syndrome Induced by Neoadjuvant Chemotherapy Containing Cisplatin – A Case Report
por: Jinsi, N, et al.
Publicado: (2022)

Effect of Zinc on Spermatogenesis and Sperm Chromatin Condensation in Bleomycin, Etoposide, Cisplatin Treated Rats
por: Razavi, Shahnaz Razavi, et al.
Publicado: (2019)

First line combination chemotherapy with cisplatin and etoposide in advanced ovarian cancer.
por: Athanassiou, A. E., et al.
Publicado: (1989)

Uncommon response of cisplatin and etoposide for treatment of advanced medullary thyroid carcinoma
por: Panomuppakarn, Nathamon, et al.
Publicado: (2017)

Comparison of Ifosfamide, Carboplatin and Etoposide versus Etoposide, Steroid, and Cytarabine Cisplatin as Salvage Chemotherapy in Patients with Refractory or Relapsed Hodgkin's lymphoma
por: Mehrzad, Valiollah, et al.
Publicado: (2017)

Four Cycles of Etoposide plus Cisplatin for Patients with Good‐Risk Advanced Germ Cell Tumors
por: Funt, Samuel A., et al.
Publicado: (2021)

Mathematical optimisation of the cisplatin plus etoposide combination for managing extensive-stage small-cell lung cancer patients
por: Faivre, C, et al.
Publicado: (2017)

Symptom relief with MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in advanced non-small-cell lung cancer.
por: Ellis, P. A., et al.
Publicado: (1995)

Combination Chemotherapy with Cyclophosphamide, Vincristine, Cisplatin and Etoposide(COPE) Combined with Radiotherapy for Small Cell Lung Cancer
por: Nam, Yong Jin, et al.
Publicado: (1995)

Retrospective study of irinotecan/cisplatin followed by etoposide/cisplatin or the reverse sequence in extensive-stage small cell lung cancer
por: Xiao, Xiaoguang, et al.
Publicado: (2015)

Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin
por: Mitry, E, et al.
Publicado: (1999)

Characterization of etoposide- and cisplatin-chemoresistant retinoblastoma cell lines
por: Busch, Maike, et al.
Publicado: (2018)

Radiotherapy prolongs the survival of advanced non-small-cell lung cancer patients undergone to an immune-modulating treatment with dose-fractioned cisplatin and metronomic etoposide and bevacizumab (mPEBev)
por: Pastina, Pierpaolo, et al.
Publicado: (2017)

Patient compliance with prolonged low-dose oral etoposide for small cell lung cancer.
por: Lee, C. R., et al.
Publicado: (1993)

Belotecan/cisplatin versus etoposide/cisplatin in previously untreated patients with extensive-stage small cell lung carcinoma: a multi-center randomized phase III trial
por: Oh, In-Jae, et al.
Publicado: (2016)

Cytotoxic therapy with etoposide and cisplatin in advanced adrenocortical carcinoma. Réseau Comète INSERM.
por: Bonacci, R., et al.
Publicado: (1998)

Unexpected favorable outcome to etoposide and cisplatin in a small cell lung cancer transformed patient: a case report
por: Xie, Zhanhong, et al.
Publicado: (2019)

In vitro and in vivo Effects of Cisplatin and Etoposide in Combination on Small Cell Lung Cancer Cell Lines
por: Kondo, Hideki, et al.
Publicado: (1994)

Randomized Phase III Trial of Irinotecan Plus Cisplatin versus Etoposide Plus Cisplatin in Chemotherapy-Naïve Korean Patients with Extensive-Disease Small Cell Lung Cancer
por: Kim, Dong-Wan, et al.
Publicado: (2019)

A Phase II Study of Vinorelbine, Mitomycin C and Cisplatin Chemotherapy for Advanced Non-Small Cell Lung Cancer
por: Kwon, Mi Ran, et al.
Publicado: (2002)

Outcome of treatment with EMA/EP (etoposide methotrexate and actinomycin-D/ etoposide and cisplatin) regimen in gestational trophoblastic neoplasia
por: Aminimoghaddam, Soheila, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_hjg1vo2qo94873vusmi0ma7nk9